IMpassion130 Phase 3 trial

August 30, 2019

Tecentriq-Abraxane Combo OK’d in EU to Treat Certain Advanced Triple-negative Breast Cancers

News

The European Commission has approved the use of Roche‘s Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) chemotherapy to treat certain adults with advanced triple-negative breast cancer (TNBC), an aggressive and difficult-to-treat malignancy. The ... Read more

July 3, 2019

CHMP Recommends Tecentriq-Abraxane Combination to Treat Some Triple-negative Breast Cancers in Europe

News

The  Committee for Medicinal Products for Human Use (CHMP),  an arm of the  European Medicines Agency , has recommended the approval of Tecentriq (atezolizumab) in combination with the chemotherapy Abraxane (nab-paclitaxel) as a ... Read more

June 24, 2019June 27, 2019

Tecentriq-Abraxane Combo Prolonging Survival in TNBC Patients, Phase 3 Trial Data Show

News

Tecentriq in combination with Abraxane, a chemotherapy, continues to prolong overall survival in adults with triple-negative breast cancer (TNBC) who test positive for the PD-L1 factor, a new interim analysis from ... Read more

March 15, 2019

FDA Grants Accelerated Approval to Tecentriq-Abraxane Combo for Some TNBC

News

The U.S. Food and Drug Administration has granted accelerated approval to a combination of Tecentriq (atezolizumab) and the chemotherapy Abraxane (nab-paclitaxel) for patients with advanced triple-negative breast cancer, making this the ... Read more

October 26, 2018

Tecentriq-Abraxane Prolongs Survival of Advanced Triple-negative Breast Cancer Patients, Study Shows

News

Combining Tecentriq (atezolizumab) with the chemotherapy Abraxane (nab-paclitaxel) extends overall survival, and survival without cancer progression, in patients with triple negative breast cancer (TNBC) whose cancer is locally advanced or ... Read more

July 9, 2018July 9, 2018

Tecentriq-Abraxane Combo Reduces Risk of Worsening Disease, Death in Metastatic Triple Negative Breast Cancer, Phase 3 Trial Shows

News

Adding Tecentriq (atezolizumab) to the chemotherapy Abraxane (nab-paclitaxel) significantly delays the time to worsening disease or death in patients with metastatic triple negative breast cancer (TNBC), a Phase 3 trial shows. The combination ... Read more